In the News
Semaglutide associated with lower stroke risk than empagliflozin
An analysis of observational data found better outcomes with semaglutide than empagliflozin, particularly in patients younger than age 65 years. Outcomes with dulaglutide were similar to those with empagliflozin.
Mifepristone improved diabetes control in hypercortisolism, industry trial finds
Patients with poorly controlled type 2 diabetes and hypercortisolism assigned to mifepristone versus placebo had lower HbA1c levels and greater reductions in body mass index and waist circumference at 24 weeks, although adverse events were common.
Fenofibrate cost-effective for preventing diabetic retinopathy progression
In diabetes patients with mild background retinopathy in both eyes or observable background retinopathy or maculopathy in one or both eyes, treatment with fenofibrate reduced the need for any referable diabetic retinopathy or treatment by 4.4% over two years, an analysis of a randomized trial found.
MKSAP quiz: Diabetes medication choice
This month's quiz asks readers to evaluate a 72-year-old man for management of newly diagnosed type 2 diabetes mellitus. He has a history of end-stage kidney disease, which is secondary to hypertension and is managed with dialysis three times weekly.
Spotlight on new drug candidates
Recent manufacturer trials assessed a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist; a combo of a GLP-1 receptor agonist and a long-acting amylin analogue; and a triple GLP-1 receptor agonist, glucose-dependent insulinotropic polypeptide, and glucagon receptor agonist.
In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo
The findings of this industry trial invite consideration of oral semaglutide in patients at high risk for major adverse cardiovascular events (MACE), provided they can handle taking the medication daily while fasting, according to an ACP Journal Club commentary.
In patients with diabetes and previous MI, high-dose multivitamins and minerals did not reduce CV events
The follow-up to the Trial to Assess Chelation Therapy did not find the cardiovascular (CV) benefits with a combination of vitamins and chelation that were seen in the initial study of patients who had a myocardial infarction (MI), an ACP Journal Club commentary noted.
Academic detailing increased deprescribing of diabetes meds in older patients
For older diabetes patients at risk of treatment-related hypoglycemia, receiving a brochure and having their physicians participate in a virtual academic detailing presentation resulted in the highest rate of medication deprescribing.
Case report describes a patient with diabetic ketoacidosis
The case explains possible pathophysiologic links between cerebral venous sinus thrombosis and diabetic ketoacidosis.